CDMO Tedor Pharma recapitalizes following multi-million dollar investment

By Melissa Fassbender

- Last updated on GMT

(Image: ozayo)
(Image: ozayo)
The newly-formed investment firm DORA Ventures has recapitalized Tedor Pharma, which recently completed a multi-million-dollar expansion of its manufacturing capabilities.

Tedor Pharma is a contract development and manufacturing company (CDMO) founded in 2001.

The company yesterday announced the closing of the recapitalization and reorganization of its business funded by investments from DORA Ventures, which is owned and controlled by Laura Iorio, chairwoman of Tedor Pharma, and Doug Drysdale, president and CEO of Tedor Pharma.

"The recapitalization was undertaken to give Tedor a strong operating runway,"​ Drysdale told us. "The next steps for Tedor are to leverage the capital investments made over the past two years to expand production capacity."

The Cumberland, RI-based CDMO recently completed a multi-million-dollar expansion of its large-scale manufacturing capabilities. The investment included the installation of new multi-purpose cGMP manufacturing suites.

"We are already seeing an increase in volumes and projects from existing customers and our business development efforts continue to create new opportunities,​" Drysdale said.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars